Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

被引：0

作者：

Rimini, M. ^{[1
]}

Amadeo, E. ^{[1
]}

Vitiello, F. ^{[2
]}

Foti, S. ^{[2
]}

Persano, M. ^{[3
]}

Tada, T. ^{[4
]}

Suda, G. ^{[5
]}

Shimose, S. ^{[6
]}

Kudo, M. ^{[7
]}

Cheon, J. ^{[8
]}

Finkelmeier, F. ^{[9
]}

Lim, H. Y. ^{[10
]}

Piscaglia, F. ^{[11
]}

Masi, G. ^{[12
]}

Yoo, C. ^{[13
]}

Lonardi, S. ^{[14
]}

Rossari, F. ^{[15
]}

Camera, S. ^{[16
]}

Gardini, A. Casadei ^{[17
]}

Presa, J. ^{[18
]}

机构：

[1] IRCCS Osped San Raffaele, Med Oncol, Milan, Italy

[2] IRCCS Osped San Raffaele, Oncol, Milan, Italy

[3] AOU Cagliari Osped Civile, Med Oncol Dept, Cagliari, Italy

[4] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[5] Hokkaido Univ, Oncol, Sapporo, Hokkaido, Japan

[6] Kurume Univ Hosp, Med Oncol Dept, Kurume, Fukuoka, Japan

[7] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[8] Ulsan Univ Hosp, Div Hematol & Oncol, Ulsan, South Korea

[9] Johannes Wolfgang Goethe Univ, Univ Klinikum Frankfurt, Dept Med Oncol, Frankfurt, Germany

[10] Sungkyunkwan Univ, Samsung Med Ctr SMC, Sch Med, Oncol, Seoul, South Korea

[11] AOU Policlin S Orsola Malpighi, Oncol, Bologna, Italy

[12] Osped Santa Chiara, Med Oncol, Pisa, Italy

[13] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[14] IOV Ist Oncol Veneto IRCCS, Oncol Dept, Padua, Italy

[15] UniSR Univ Vita Salute San Raffaele Milano, Dept Med Oncol SR Tiget, Milan, Italy

[16] IRCCS Osped San Raffaele, Dipartimento Oncol Med, Milan, Italy

[17] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[18] Ras Os Montes Alto Douro Hosp Ctr, Oncol, Vila Real, Portugal

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.767

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

188P

引用

页码：S1548 / S1548

页数：1

共 50 条

[1] Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
Rimini, Margherita
Montes, Margarida
Amadeo, Elisabeth
Vitiello, Francesco
Kudo, Masatoshi
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Lonardi, Sara
Finkelmeier, Fabian
Salani, Francesca
Antonuzzo, Lorenzo
Marra, Fabio
Iavarone, Massimo
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Sacco, Rodolfo
Rapposelli, Ilario Giovanni
Scartozzi, Mario
Nicoletta, Pella
Aldrighetti, Luca
Persano, Mara
Camera, Silvia
Rossari, Federico
Foti, Silvia
Kumada, Takashi
Hiraoka, Atsushi
Iwamoto, Hideki
Rizzato, Mario Domenico
Himmelsbach, Vera
Masi, Gianluca
Corradi, Mattia
Celsa, Ciro
Fabio, Conti
Frassineti, Giovanni Luca
Cascinu, Stefano
Casadei-Gardini, Andrea
Presa, Jose
SCIENTIFIC REPORTS, 2024, 14 (01):
[2] BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Amadeo, E.
Persano, M.
Tada, T.
Suda, G.
Shimose, S.
Kudo, M.
Yoo, C.
Rossari, F.
Vitiello, F.
Gardini, A. Casadei
Rimini, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1539 - S1540
[3] Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab
Rimini, Margherita
Stefanini, Bernardo
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Finkelmeier, Fabian
Yoo, Changhoon
Presa, Jose
Amadeo, Elisabeth
Genovesi, Virginia
De Grandis, Maria Caterina
Iavarone, Massimo
Marra, Fabio
Foschi, Francesco
Tamburini, Emiliano
Rossari, Federico
Vitiello, Francesco
Bartalini, Linda
Solda, Caterina
Tovoli, Francesco
Vivaldi, Caterina
Lonardi, Sara
Silletta, Marianna
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Himmelsbach, Vera
Montes, Margarida
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
LIVER INTERNATIONAL, 2024, 44 (05) : 1108 - 1125
[4] Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib
Hiraoka, Atsushi
Kumada, Takashi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Naganuma, Atsushi
Kosaka, Hisashi
Shibata, Hiroshi
Aoki, Tomoko
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Kouji
Iijima, Hiroko
Kaibori, Masaki
Hiasa, Yoichi
Kudo, Masatoshi
CANCER MEDICINE, 2023, 12 (01): : 325 - 334
[5] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shigeo, Shimose
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Piscaglia, Fabio
Iavarone, Massimo
Di Costanzo, Giuseppe
Marra, Fabio
Cabibbo, Giuseppe
Foschi, Francesco
Siletta, Marianna
Cascinu, Stefano
Scartozzi, Mario
Gardini, Andrea Casadei
JOURNAL OF HEPATOLOGY, 2023, 78 : S593 - S594
[6] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
Persano, M.
Rimini, M.
Toshifumi, T.
Suda, G.
Shigeo, S.
Kudo, M.
Cheon, J.
Finkelmeier, F.
Presa, J.
Masi, G.
Yoo, C.
Lonardi, S.
Tovoli, F.
Piscaglia, F.
Iavarone, M.
Marra, F.
Tamburini, E.
Cabibbo, G.
Scartozzi, M.
Casadei-Gardini, A.
ANNALS OF ONCOLOGY, 2023, 34 : S6 - S7
[7] IMPACT OF FIRST- LINE SYSTEMIC THERAPY WITH ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HCC
Aoe, Kaho
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Hirooka, Masashi
Kariyama, Kazuya
Itobayashi, Ei
Kunihiko, Tsuji
Ishikawa, Toru
Toyoda, Hidenori
Hatanaka, Takeshi
Kakizaki, Satoru
Ohama, Hideko
Tada, Fujimasa
Nouso, Kazuhiro
Hiasa, Yoichi
HEPATOLOGY, 2023, 78 : S1852 - S1853
[8] Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma
Su, Chung-Wei
Teng, Wei
Lin, Po-Ting
Jeng, Wen-Juei
Chen, Kuei-An
Hsieh, Yi-Chung
Chen, Wei-Ting
Ho, Ming-Mo
Hsieh, Chia-Hsun
Wang, Ching-Ting
Chai, Pei-Mei
Lin, Chen-Chun
Lin, Chun-Yen
Lin, Shi-Ming
CANCER MEDICINE, 2023, 12 (06): : 7077 - 7089
[9] HIGHER RISK OF PROTEINURIA IN ATEZOLIZUMAB PLUS BEVACIZUMAB THAN LENVATINIB AS A FIRST-LINE SYSTEMIC TREATMENT IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
Yang, Jiwon
HEPATOLOGY, 2024, 80
[10] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Tovoli, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Niizeki, Takashi
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Stefanini, Bernardo
Hiraoka, Atsushi
Sho, Takuya
Nishida, Naoshi
Steup, Christoph
Iavarone, Massimo
Di Costanzo, Giovanni
Marra, Fabio
Tamburini, Emiliano
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
EUROPEAN JOURNAL OF CANCER, 2023, 189

← 1 2 3 4 5 →